Cheng Alice Y Y, Heine Robert J, Del Prato Stefano, Green Jennifer B, Thieu Vivian Thuyanh, Zeytinoglu Meltem
Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Eli Lilly and Company, Indianapolis, Indiana, USA.
Diabetes Obes Metab. 2025 Apr;27(4):1708-1718. doi: 10.1111/dom.16206. Epub 2025 Jan 28.
Despite the recognition by key guidelines that achieving early glycaemic control has important benefits in individuals with type 2 diabetes (T2D) and that addressing excess adiposity is one of the central components of comprehensive person-centred T2D care, a substantial proportion of individuals with T2D do not meet their metabolic treatment goals. Prior treatment paradigms were limited by important treatment-associated risks such as hypoglycaemia and body weight gain. Therefore, a more conservative, sequential approach to treatment was typically utilized. One potential consequence of this approach has been a missed opportunity to achieve a 'legacy effect', where early treatment to reach glycaemic targets is associated with enduring long-term benefits in T2D. Additionally, while previous treatment approaches have addressed core defects in T2D, including insulin resistance and β-cell function decline, they have been unable to address one of the underlying causal abnormalities-excess adiposity. Here, we review currently available evidence for the beneficial long-term effects of early glycaemic control and management of body weight in people with T2D and discuss potential next steps.
尽管关键指南已认识到,早期血糖控制对2型糖尿病(T2D)患者具有重要益处,且解决肥胖问题是以人为本的综合T2D护理的核心组成部分之一,但仍有很大比例的T2D患者未达到其代谢治疗目标。先前的治疗模式受到低血糖和体重增加等与治疗相关的重大风险的限制。因此,通常采用更为保守的序贯治疗方法。这种方法的一个潜在后果是错失了实现“遗留效应”的机会,即早期达到血糖目标的治疗与T2D患者长期持续获益相关。此外,虽然先前的治疗方法已解决了T2D的核心缺陷,包括胰岛素抵抗和β细胞功能下降,但它们无法解决潜在的因果异常之一——肥胖。在此,我们综述了目前关于早期血糖控制和体重管理对T2D患者长期有益影响的现有证据,并讨论了潜在的下一步措施。